SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

2 marketing jobs

PharmaEssentia logo
1 day ago

Senior Manager, Peer to Peer Marketing

PharmaEssentia

Burlington, MA (Unknown)Full time$138K/yr – $179K/yr
PharmaEssentia logo
1 day ago

Senior Manager, Digital Marketing

PharmaEssentia

Burlington, MA (Hybrid)Full time$138K/yr – $179K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
PharmaEssentia logo

Senior Manager, Peer to Peer Marketing

PharmaEssentia

Burlington, MA (Unknown)

$138K/yr - $179K/yrIn-houseFull-timeSenior level7+ years exp.
1 day ago
PharmaEssentia logo

Senior Manager, Digital Marketing

PharmaEssentia

Burlington, MA (Hybrid)

$138K/yr - $179K/yrIn-houseFull-timeSenior level5+ years exp.
1 day ago
PharmaEssentia logo
PharmaEssentia

Senior Manager, Peer to Peer Marketing

Burlington, MA (Unknown)

$138K/yr – $179K/yrSenior Level7+ years expFull time

Posted 1 day ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own and drive the end-to-end advisory, P2P education, and KOL engagement programs, turning HCP insights into actionable brand strategies and cross-functional initiatives.

  • Lead advisory boards and P2P education initiatives with cross-functional partners
  • Manage KOL relationships and ensure compliant, impactful education programs
  • Collaborate with Brand, Medical Affairs, Sales, and Legal to execute strategic programs

Job Description

Responsibilities

  • Advisory Boards & Insight Generation:
  • Lead advisory board strategy and execution, including objectives, key business questions, KOL selection, agenda development, contracting, facilitation, and post-meeting deliverables.
  • Partner with cross-functional stakeholders to ensure advisory boards address meaningful strategic questions and generate actionable insights.
  • Synthesize HCP and KOL perspectives into clear themes and recommendations that inform brand strategy, educational priorities, and customer engagement.
  • Establish effective processes for sharing insights and recommendations with senior leadership and relevant cross-functional teams.
  • Peer-to-Peer Education & Strategy:
  • Develop and execute the P2P education strategy in alignment with brand objectives and HCP educational needs.
  • Build, launch, and evolve P2P platforms and programs across live, virtual, and hybrid channels.
  • Translate brand strategy into relevant, compelling, and compliant HCP educational experiences.
  • Partner with Brand and Medical Affairs to ensure P2P content is strategically aligned, scientifically rigorous, and responsive to HCP needs.

Requirements

  • Bachelor's degree in Business, Marketing, Life Sciences, or related field.
  • 5–7+ years of progressive commercial pharmaceutical or biotechnology experience.
  • Hematology-Oncology and/or Rare Disease experience strongly preferred
  • Minimum of 3 years of experience in commercial, brand marketing, medical education, P2P education, and/or KOL management.
  • Experience leading advisory boards and translating HCP and KOL insights into actionable brand and commercial strategies.
  • Demonstrated success developing and executing HCP engagement and P2P education strategies within rare disease or other highly specialized markets.
  • Strong understanding of healthcare compliance requirements related to HCP engagement, advisory boards, and speaker programs.
  • Demonstrated experience engaging and building productive relationships with national and regional KOLs.
  • Experience supporting product launches and/or growth-stage brands.
  • Strong executive presence with the ability to engage senior commercial leadership, KOLs, and cross-functional stakeholders.

Benefits

  • Comprehensive medical coverage
  • Dental and vision coverage
  • Generous paid time-off
  • 401(k) retirement plan with competitive company match
  • Medical & Dependent Care Flexible Spending Account
  • Up to $150 monthly cell phone reimbursement
  • Employee Assistance Program
PharmaEssentia logo

PharmaEssentia

4.0 Glassdoor

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology, and immunology. Founded in 2003, PharmaEssentia is now expanding its global presence with operations in the U.S., Japan, China and Korea.

Founded in 2003
Burlington, Massachusetts, USA
337 employees (10 in marketing)
us.pharmaessentia.com
72% recommend to a friend

Salaries

Posted range

$138K/yr – $179K/yr

Taken straight from the job posting.

See all PharmaEssentia salaries

Marketing Team

Marketing Team Size
10 (3% of company)
Median Career Experience
20 years
Median Tenure
2 years
Marketing Roles Posted (Last 30 Days)
2

People

HR / Recruitment

Adam Lentz
Adam Lentz
Director Talent Acquisition
At the company for 3 months

Marketing Leadership

Adam Lentz
Adam Lentz
Director Talent Acquisition
At the company for 3 months

Funding

Total Funding
$462.7M
Last Raise
$462.7M
Post IPO Equity, 3 years ago

Funding History

  • Apr 2023
    Post IPO Equity • $462.7M
  • Aug 2022
    Post IPO Equity

Traffic Signals

Monthly Visitors
17.5K
Traffic Source Mix
Search
46.3%
Direct
44.6%
Referral
5.3%
Social
2.6%
Paid
1.1%

Headcount Trend

Current headcount: ~338

Recent News

Besremi gains reimbursement as second-line therapy for polycythemia vera in Korea
Aug 27, 2025 • koreabiomed.com
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 18, 2025 • Business Wire
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 18, 2025 • BioSpace
Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia
Jul 25, 2025 • Research and Markets
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
Jun 4, 2025 • BioSpace
Polycythemia Vera Market Shifts Toward Novel Mechanisms and Long-Term Disease Control | Competitive Intelligence
Jun 4, 2025 • EIN Presswire
ASCO25: PharmaEssentia's Besremi hits mark in late-stage thrombocythaemia study
Jun 3, 2025 • FirstWord Pharma
PharmaEssentia eyes expanded US use of Besremi after positive Phase III data
Jun 3, 2025 • Pharma Letter
Regulatory actions for March 24, 2025
Mar 24, 2025 • BioWorld Financial Watch
Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera
Mar 20, 2025 • StreetInsider.com
Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera
Mar 20, 2025 • Business Wire
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
Mar 5, 2025 • BioSpace
Essential Thrombocythemia Market to Witness Upsurge in Growth During the Study Period (2020–2034) | DelveInsight
Mar 5, 2025 • GlobeNewswire News Room
Besremi Global Market Report 2025: A Comprehensive Analysis Of Key Growth Drivers, Trends, and Opportunities
Mar 4, 2025 • EIN Presswire
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
Feb 26, 2025 • prnewswire.co.uk
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
Feb 26, 2025 • PR Newswire
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment
Feb 20, 2025 • GlobeNewswire News Room
Ropeginterferon Alfa-2b Effective in Essential Thrombocythemia Trial
Jan 28, 2025 • Hematology Advisor
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
Jan 7, 2025 • Fierce Pharma
PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Jan 6, 2025 • BioSpace
PharmaEssentia nabs MorphoSys GM Horvat to lead its commercial team
Dec 6, 2024 • Fierce Pharma
PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer
Dec 5, 2024 • citybiz
FORUS Therapeutics Inc. and PharmaEssentia Corporation Have Entered Into an Exclusive Licensing Agreement for The Registration and Distribution of BESREMi(R) (ropeginterferon alfa-2b) for The Treatment of polycythemia vera (PV), in Canada
Oct 31, 2024 • Yahoo Finance
Pharmaessentia Announces Licensing Agreement with Forus Therapeutics to Commercialize Besremi® (Ropeginterferon Alfa-2B-Njft) in Canada
Sep 4, 2024 • MarketScreener
PharmaEssentia Appoints Beth A. Krewson as Head of Legal
Jul 22, 2024 • Business Wire
PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
Jul 8, 2024 • Business Wire
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
Jul 1, 2024 • Business Wire
PharmaEssentia Appoints Fred Paster as Head of Commercial
Jun 20, 2024 • Yahoo Finance
PharmaEssentia Appoints Fred Paster as Head of Commercial
Jun 20, 2024 • Business Wire
Pharmaessentia raises $462M in GDR offering to expand global footprint
Jan 1, 1970 • http://www.zdnet.com/
PharmaEssentia, WuXi Biologics Ink Exclusive Global License Agreement
Jan 1, 1970
PharmaEssentia Acquires Myeloid Immune Checkpoint Antibody from WuXi Biologics
Jan 1, 1970 • China Bio Today
Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center
Jan 1, 1970 • PRNewswire
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune ...
Jan 1, 1970
PharmaEssentia secures $462M+ to further growth of Besremi and its pipeline
Jan 1, 1970 • Endpoints News
PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America
Jan 1, 1970 • BioSpace
PharmaEssentia Included in FTSE Russell Indices
Jan 1, 1970 • Business Wire
IDBS announces data management partnership with PharmaEssentia Innovation Research Center
Jan 1, 1970 • PR Newswire
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
Jan 1, 1970 • Business Wire
PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer
Jan 1, 1970 • Biospace
PharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy
Jan 1, 1970 • Biospace
PharmaEssentia takes Besremi rare blood cancer message to consumers
Jan 1, 1970 • Endpoints News
PharmaEssentia's BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive ...
Jan 1, 1970
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
Jan 1, 1970 • PharmiWeb.com
Global Actinic Keratosis Treatment Market Share, Analysis ...
Jan 1, 1970 • menafn
PharmaEssentia Enters Into Exclusive Global License ...
Jan 1, 1970 • BioSpace
PharmaEssentia Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Jan 1, 1970

Links

us.pharmaessentia.comLinkedInX (Twitter)Crunchbase